

Murray B Urowitz

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1200276/murray-b-urowitz-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

188 papers	18,891 citations	52 h-index	136 g-index
214 ext. papers	22,385 ext. citations	4.6 avg, IF	6.16 L-index

#	Paper	IF	Citations
188	Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. <i>Arthritis and Rheumatism</i> , 1992 , 35, 630-40		3596
187	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2677-86		2688
186	The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1996 , 39, 363-9		1688
185	Systemic lupus erythematosus disease activity index 2000. <i>Journal of Rheumatology</i> , 2002 , 29, 288-91	4.1	1602
184	The bimodal mortality pattern of systemic lupus erythematosus. <i>American Journal of Medicine</i> , 1976 , 60, 221-5	2.4	735
183	The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1997 , 40, 809-13		505
182	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1400-1412	9.5	488
181	Systemic lupus erythematosus. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16039	51.1	422
180	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1151-1159	2.4	344
179	Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. <i>Arthritis and Rheumatism</i> , 2003 , 48, 3159-67		271
178	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1706-13	2.4	250
177	Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2008 , 35, 2152-8	4.1	229
176	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016 , 55, 252-62	3.9	210
175	The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010 , 62, 863-8		203
174	Cancer risk in systemic lupus: an updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013 , 42, 130-5	15.5	194
173	Accrual of organ damage over time in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2003 , 30, 1955-9	4.1	185
172	Malignancy in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1996 , 39, 1050-4		179

171	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 554-561	2.4	175
170	Lupus retinopathy. Patterns, associations, and prognosis. <i>Arthritis and Rheumatism</i> , 1988 , 31, 1105-10		161
169	Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. <i>American Journal of Medicine</i> , 1979 , 66, 210-5	2.4	117
168	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1502-9	2.4	115
167	Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. <i>Journal of Rheumatology</i> , 2003 , 30, 1977-82	4.1	108
166	Premature atherosclerosis in systemic lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2000 , 26, 257-78	2.4	101
165	Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. <i>Journal of Rheumatology</i> , 2005 , 32, 824-7	4.1	97
164	Peripheral neuropathy in patients with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 41, 203-11	5.3	94
163	The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort. <i>Journal of Rheumatology</i> , 2009 , 36, 1200-8	4.1	92
162	Pregnancy outcome following first trimester exposure to chloroquine. <i>American Journal of Perinatology</i> , 1991 , 8, 174-8	3.3	92
161	Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. <i>Arthritis and Rheumatism</i> , 1992 , 35, 849-56		91
160	Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. <i>Journal of Rheumatology</i> , 2010 , 37, 1822-7	4.1	90
159	Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1152-8		90
158	Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. <i>Journal of Rheumatology</i> , 2011 , 38, 69-78	4.1	84
157	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 138-42	2.4	83
156	Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. <i>Journal of Rheumatology</i> , 2007 , 34, 70-5	4.1	83
155	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 543-546	2.4	80
154	The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2013 , 40, 831-41	4.1	79

153	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1837-47	9.5	77
152	Prolonged remission in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2005 , 32, 1467-72	4.1	76
151	Premature atherosclerosis in systemic lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2005 , 31, 329-54, vii-viii	2.4	75
150	Prolonged clinical remission in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2014 , 41, 1808-16	4.1	68
149	Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2887-97		65
148	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1308-14	2.4	65
147	The SLICC/ACR damage index: progress report and experience in the field. <i>Lupus</i> , 1999 , 8, 632-7	2.6	64
146	Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. <i>Arthritis Research and Therapy</i> , 2011 , 13, R156	5.7	61
145	Incidence rates of arterial and venous thrombosis after diagnosis of systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005 , 53, 609-12		61
144	Kidney biopsy in systemic lupus erythematosus. II. Survival analyses according to biopsy results. <i>Arthritis and Rheumatism</i> , 1991 , 34, 1268-73		61
143	Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1837-1844	2.4	60
142	Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. <i>Arthritis Care and Research</i> , 2012 , 64, 511-8	4.7	60
141	Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. <i>Journal of Rheumatology</i> , 2014 , 41, 688-97	4.1	57
140	Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2009 , 36, 2454-61	4.1	57
139	Dyslipidemia in systemic lupus erythematosus: just another comorbidity?. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 604-10	5.3	56
138	Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables. <i>Arthritis and Rheumatism</i> , 1994 , 37, 559-67		56
137	Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. <i>Journal of Rheumatology</i> , 2011 , 38, 275-84	4.1	54
136	All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013). <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 802-806	2.4	52

135	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1530-6	2.4	51
134	The significance of thrombocytopenia in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1983 , 26, 1181-6		51
133	Contributions of observational cohort studies in systemic lupus erythematosus: the university of toronto lupus clinic experience. <i>Rheumatic Disease Clinics of North America</i> , 2005 , 31, 211-21, v	2.4	48
132	Optimal Monitoring For Coronary Heart Disease Risk in Patients with Systemic Lupus Erythematosus: A Systematic Review. <i>Journal of Rheumatology</i> , 2016 , 43, 54-65	4.1	47
131	Persistent proteinuria and dyslipidemia increase the risk of progressive chronic kidney disease in lupus erythematosus. <i>Kidney International</i> , 2011 , 79, 914-20	9.9	47
130	Modified Framingham Risk Factor Score for Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2016 , 43, 875-9	4.1	46
129	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019 , 71, 893-902	4.7	46
128	Defining Low Disease Activity in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017 , 69, 997-1003	4.7	45
127	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. <i>Arthritis and Rheumatism</i> , 2000 , 13, 406-408		44
126	Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. <i>Current Rheumatology Reviews</i> , 2017 , 13, 206-218	1.6	43
125	Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2006 , 33, 1990-5	4.1	41
124	Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. <i>Lupus Science and Medicine</i> , 2015 , 2, e000104	4.6	39
123	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1478-1487	4.7	36
122	The effect of menopause on disease activity in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2006 , 33, 2192-8	4.1	36
121	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 634-640	2.4	35
120	Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. <i>Journal of Rheumatology</i> , 2006 , 33, 1785-8	4.1	35
119	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018 , 45, 1426-1439	4.1	33
118	Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study. <i>Journal of Rheumatology</i> , 2017 , 44, 1841-1849	4.1	32

117	Epidemiology of atherosclerosis in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2009 , 11, 248-54	4.9	32
116	Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 372-379	2.4	32
115	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 281-289	9.5	31
114	Interferon- γ Induces altered transitional B cell signaling and function in Systemic Lupus Erythematosus. <i>Journal of Autoimmunity</i> , 2015 , 58, 100-10	15.5	29
113	Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? a critical appraisal. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 43, 521-5	5.3	28
112	Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus. <i>Rheumatology</i> , 2015 , 54, 449-57	3.9	28
111	Asymptomatic spondylodiscitis. An unusual feature of ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 1974 , 17, 487-93		28
110	Atherosclerosis and systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2000 , 2, 19-23	4.9	27
109	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1932-44	9.5	27
108	Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study. <i>Journal of Rheumatology</i> , 2016 , 43, 552-8	4.1	26
107	Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2009 , 36, 288-94	4.1	26
106	Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019 , 71, 822-828	4.7	25
105	⁶⁷ Gallium lung scans in progressive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1983 , 26, 969-74		25
104	Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnormalities. <i>Journal of Rheumatology</i> , 2003 , 30, 288-91	4.1	25
103	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018 , 45, 393-396	4.1	23
102	Accelerated nodulosis during azathioprine therapy. <i>Arthritis and Rheumatism</i> , 1991 , 34, 123-4		23
101	Summarizing disease features over time: II. Variability measures of SLEDAI-2K. <i>Journal of Rheumatology</i> , 2007 , 34, 336-40	4.1	23
100	Hospitalizations in Patients with Systemic Lupus Erythematosus in an Academic Health Science Center. <i>Journal of Rheumatology</i> , 2017 , 44, 1173-1178	4.1	21

99	Anti-dsDNA and Antichromatin Antibody Isotypes in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2015 , 42, 810-6	4.1	21
98	Comparison of three anti-dsDNA assays: performance and correlation with systemic lupus erythematosus disease activity. <i>Clinical Biochemistry</i> , 2013 , 46, 317-20	3.5	21
97	Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2211-9		21
96	Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. <i>Rheumatology</i> , 2020 , 59, 90-98	3.9	21
95	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2020 , 47, 72-81	4.1	21
94	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1-2	2.4	21
93	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018 , 57, 677-687	3.9	20
92	Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011 , 63, 1517-20	4.7	20
91	Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2010 , 12, R125	5.7	20
90	Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients. <i>Rheumatology</i> , 2012 , 51, 528-34	3.9	20
89	Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered?. <i>Journal of Rheumatology</i> , 2019 , 46, 391-396	4.1	20
88	Systemic lupus erythematosus: an update on current pharmacotherapy and future directions. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 723-37	5.4	19
87	Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies. <i>Open Access Rheumatology: Research and Reviews</i> , 2017 , 9, 1-9	2.4	19
86	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 356-362	2.4	18
85	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020 , 72, 67-77	9.5	18
84	Costs associated with severe and nonsevere systemic lupus erythematosus in Canada. <i>Arthritis Care and Research</i> , 2015 , 67, 431-6	4.7	17
83	Impact of the new American College of Cardiology/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 612-617	2.4	17
82	American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. <i>Journal of Rheumatology</i> , 2014 , 41, 875-80	4.1	17

81	Psoriasis in systemic lupus erythematosus: a single-center experience. <i>Clinical Rheumatology</i> , 2017 , 36, 879-884	3.9	16
80	A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. <i>Rheumatology</i> , 2018 , 57, 1370-1376	3.9	16
79	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1333-1339	2.4	16
78	Hydroxychloroquine-Induced Cardiomyopathy in Systemic Lupus Erythematosus. <i>Journal of Clinical Rheumatology</i> , 2016 , 22, 287-8	1.1	16
77	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1297-1307	9.5	15
76	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020 , 106, 102340	15.5	15
75	How can we define low disease activity in systemic lupus erythematosus?. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 48, 1035-1040	5.3	15
74	Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2015 , 42, 2318-26	4.1	14
73	Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. <i>Journal of Rheumatology</i> , 2013 , 40, 630-3	4.1	14
72	Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015 , 17, 296	5.7	13
71	High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3052-3		13
70	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018 , 70, 1294-1302	4.7	13
69	Switching treatment between mycophenolate mofetil and azathioprine in lupus patients: indications and outcomes. <i>Arthritis Care and Research</i> , 2014 , 66, 1905-9	4.7	12
68	Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time. <i>Journal of Rheumatology</i> , 2011 , 38, 60-3	4.1	12
67	More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018 , 45, 90-94	4.1	12
66	Role of specialty care in the management of patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2002 , 29, 1207-10	4.1	12
65	Outcomes in patients with active lupus nephritis requiring immunosuppressives who never received cyclophosphamide. <i>Journal of Rheumatology</i> , 2007 , 34, 1491-6	4.1	12
64	Isolated hematuria and sterile pyuria may indicate systemic lupus erythematosus activity. <i>Journal of Rheumatology</i> , 2015 , 42, 437-40	4.1	11

63	Studies into the occurrence of soluble antigen-antibody complexes in disease. V. Second assessment of correlation between the rheumatoid biologically active factor (RBAF) and the clinical features of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1973 , 16, 225-30		11
62	Atherosclerotic Vascular Events in Systemic Lupus Erythematosus: An Evolving Story. <i>Journal of Rheumatology</i> , 2020 , 47, 66-71	4.1	11
61	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020 , 72, 658-666	9.5	11
60	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021 , 73, 1231-1235	4.7	10
59	Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada. <i>Journal of Rheumatology</i> , 2018 , 45, 1440-1447	4.1	10
58	Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials?. <i>Journal of Rheumatology</i> , 2019 , 46, 64-69	4.1	10
57	Mixed leukocyte reaction in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1976 , 19, 532-8		10
56	Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. <i>Rheumatology</i> , 2021 , 60, 5397-5407	3.9	10
55	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	10
54	Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease. <i>Arthritis Research and Therapy</i> , 2017 , 19, 31	5.7	9
53	Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case-Control Study. <i>Arthritis Care and Research</i> , 2016 , 68, 1497-504	4.7	9
52	The SLICC inception cohort for atherosclerosis. <i>Current Rheumatology Reports</i> , 2008 , 10, 281-5	4.9	9
51	Systemic lupus erythematosus and diffuse soft tissue calcifications. <i>International Journal of Dermatology</i> , 1983 , 22, 416-8	1.7	9
50	The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2021 , 23, 29	5.7	9
49	Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. <i>Rheumatology</i> , 2018 , 57, 125-133	3.9	8
48	Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort. <i>Journal of Rheumatology</i> , 2021 , 48, 67-73	4.1	8
47	Disease Outcomes in Glucocorticosteroid-Naïve Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017 , 69, 252-256	4.7	7
46	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019 , 46, 492-500	4.1	7

45	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1734-1740	9.5	7
44	Outcome measures in systemic lupus erythematosus. <i>Indian Journal of Rheumatology</i> , 2013 , 8, S46-S53	0.5	7
43	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020 , 72, 1800-1808	4.7	7
42	Monophasic Disease Course in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018 , 45, 1131-1135	4.1	6
41	Should all patients with systemic lupus erythematosus receive cardioprotection with statins?. <i>Nature Clinical Practice Rheumatology</i> , 2007 , 3, 536-7		6
40	New EULAR/ACR 2019 SLE Classification Criteria: defining ominousness in SLE. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	6
39	Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics. <i>Clinical Rheumatology</i> , 2017 , 36, 1773-1778	3.9	5
38	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019 , 58, 1259-1267	3.9	5
37	SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement. <i>Journal of Rheumatology</i> , 2015 , 42, 1401-5	4.1	5
36	The clinical significance of immune complexes in rheumatoid disease. <i>Annals of the New York Academy of Sciences</i> , 1975 , 256, 338-41	6.5	5
35	Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	5
34	FRI0195 EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL (DZP) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): A RANDOMISED, PLACEBO (PBO)-CONTROLLED STUDY 2019 ,		5
33	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , 2021 , 60, 4737-4747	3.9	5
32	Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index. <i>Arthritis Care and Research</i> , 2021 , 73, 1243-1249	4.7	5
31	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	5
30	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	4
29	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1010-1012	2.4	4
28	Propensity Score Methods in Rare Disease: A Demonstration Using Observational Data in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2021 , 48, 321-325	4.1	4

27	Acquired low immunoglobulin levels and risk of clinically relevant infection in adult patients with systemic lupus erythematosus: a cohort study. <i>Rheumatology</i> , 2021 , 60, 1456-1464	3.9	4
26	The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 46, 791-797	5.3	3
25	Clinical Measures, Metrics, and Indices 2013 , 563-581		3
24	Medium versus high initial prednisone dose for remission induction in lupus nephritis: A propensity score matched analysis. <i>Arthritis Care and Research</i> , 2021 ,	4.7	3
23	Assessment of cardiovascular risk tools as predictors of cardiovascular disease events in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	3
22	Systemic Glucocorticoids 2016 , 521-531		3
21	Advanced Chronic Kidney Disease in Lupus Nephritis: Is Dialysis Inevitable?. <i>Journal of Rheumatology</i> , 2020 , 47, 1366-1373	4.1	3
20	Immunoglobulin levels in systemic lupus erythematosus: A narrative review. <i>Lupus</i> , 2021 , 30, 867-875	2.6	3
19	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence 2000 , 13, 406		3
18	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , 2020 ,	4.7	2
17	Rituximab for Sight-Threatening Lupus-Related Retinal Vasculitis. <i>Journal of Clinical Rheumatology</i> , 2018 , 24, 93-94	1.1	2
16	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , 2021 , 73, 1789-1795	4.7	2
15	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021 , 30, 1283-1288	2.6	2
14	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2293-2302	9.5	2
13	Barriers to medication adherence and degree of nonadherence in a systemic lupus erythematosus (SLE) outpatient population. <i>Rheumatology International</i> , 2021 , 41, 1457-1464	3.6	2
12	Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , 2021 , 3, 550-557	3.5	2
11	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017 , 19, 287	5.7	1
10	In memoriam - Hugh A. Smythe, 1927-2012. <i>Journal of Rheumatology</i> , 2013 , 40, 343-7	4.1	1

9	Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis. <i>Rheumatology</i> , 2021 , 60, 73-80	3.9	1
8	Factors Associated With Rapid Progression to Endstage Kidney Disease in Lupus Nephritis. <i>Journal of Rheumatology</i> , 2021 , 48, 228-231	4.1	1
7	Dr. Tselios, et al reply. <i>Journal of Rheumatology</i> , 2016 , 43, 1767	4.1	
6	Dr. Tselios, reply. <i>Journal of Rheumatology</i> , 2019 , 46, 1422	4.1	
5	Reply. <i>Arthritis Care and Research</i> , 2017 , 69, 1934	4.7	
4	Differential Diagnosis and Disease Associations 2019 , 598-605		
3	Systemic glucocorticoids 2021 , 597-609		
2	Metrics in Disease Activity Measures in Systemic Lupus Erythematosus 2021 , 111-146		
1	Response to: Correspondence on "New EULAR/ACR 2019 SLE classification criteria: defining ominousness in SLE" by Whittall Garcia. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	